New cancer drug TORL-1-23 enters first human tests

NCT ID NCT05103683

Recruiting now Disease control Sponsor: TORL Biotherapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find the right dose, and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TORL-1-23 (an antibody drug conjugate)
What this could lead to: If successful, this could point toward a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 90 participants, so it is too soon to know if it works. Side effects are unknown, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm neoplasm non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR ENDOMETRIAL CANCER NSCLC OVARIAN CANCER

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Providence Medical Foundation
RECRUITING

Fullerton, California, 92835, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Sarah Cannon Research Institute Texas Oncology
RECRUITING

Tyler, Texas, 75702, United States
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital
RECRUITING

Seoul, 03723, South Korea
St. Vincent's Hospital, The Catholic University of Korea
RECRUITING

Suwon, Gyeonggi-do, 16247, South Korea
UCLA - JCCC Clinical Research Unit
RECRUITING

Los Angeles, California, 90095, United States
University of Kentucky Medical Center
RECRUITING

Lexington, Kentucky, 40536, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.